Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.84
-0.0200-0.52%
Pre-market: 3.850.0100+0.26%04:00 EDT
Volume:786.21K
Turnover:3.01M
Market Cap:120.15M
PE:-0.93
High:3.90
Open:3.90
Low:3.75
Close:3.86
52wk High:50.40
52wk Low:3.60
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.97
T/O Rate:4.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.55
PE(LYR):-1.35

Loading ...

Quince Therapeutics Raised to Market Outperform from Market Perform by Citizens

Dow Jones
·
Sep 22

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

GlobeNewswire
·
Sep 22

Kazia Therapeutics Gains $2 Million Milestone as Sovargen Doses First Paxalisib Patient in Rare Epilepsy Trial

TIPRANKS
·
Sep 22

Marker Therapeutics highlights expanded manufacturing support of CDMO partner

TIPRANKS
·
Sep 22

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

GlobeNewswire
·
Sep 22

Decoy Therapeutics to explore pan-filovirus program via FDA Animal Rule pathway

TIPRANKS
·
Sep 22

Viridian Therapeutics price target raised to $38 from $36 at RBC Capital

TIPRANKS
·
Sep 22

Leerink Partners Initiates Obsidian Therapeutics at Outperform With $32 Price Target

MT Newswires Live
·
Sep 22

Travere Therapeutics: Buy Rating Reiterated as CEO Transition Seen as Non-Disruptive, $67 Price Target Unchanged

TIPRANKS
·
Sep 22

RBC Raises Price Target on Viridian Therapeutics to $38 From $36, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Sep 22

Travere Therapeutics Price Target Maintained with a $67.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 22

Obsidian Therapeutics initiated with an Outperform at Leerink

TIPRANKS
·
Sep 22

Iambic Therapeutics Files for Nasdaq IPO

MT Newswires Live
·
Sep 22

Chimeric Therapeutics Seeks Quotation for 22.2 Million New Shares on ASX

TIPRANKS
·
Sep 22

Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics today

TIPRANKS
·
Sep 22

These Beaten-Down Stocks Could Bounce Back in January, if History is Any Guide

Dow Jones
·
Sep 22

Travere Therapeutics appoints new CEO Bradley Campbell

TIPRANKS
·
Sep 22

AI Drug Discovery Firm Iambic Therapeutics Files for IPO

Dow Jones
·
Sep 22

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference

GlobeNewswire
·
Sep 22

Travere Therapeutics CEO Dube to step down

TIPRANKS
·
Sep 22